## What is claimed is:

) 1. An isolated antibody generated against the propertide of the Int1p protein of Candida albicans.

- 2. An isolated antibody according to claim 1 wherein the propertide has the sequence of amino acids 1-263 of the Int1p protein as shown in Fig. 1.
- 3. An isolated antibody according to claim 1 wherein said antibody is capable of preventing the cleaving of the propertide.
  - 4. Isolated antisera containing an antibody according to Claim 1.
- 5. A method of treating or preventing an infection by a microorganism expressing the Int1p protein comprising administering an effective amount of the antibody according to claim 1 to a human or animal patient.
- 6. A method according to claim 5 wherein the microorganism is selected from the group consisting of *Candida albicans* and *Saccharomyces* cerevisiae.
- 7. A method according to claim 5 wherein the antibody is raised to a portion of the propertide of Int1p effective to generate an immune response.
- 8. A method for treating patients exposed to *Candida albicans* in the presence of heparin, the method comprising:

administering the antibody according to claim 1 to a human or animal patient in an amount effective to bind with the heparin and to reduce or eliminate the activation of the Int1p protein.

- 9. A pharmaceutical composition for treating or preventing an infection from a microorganism expressing the Int1p protein comprising an effective amount of an isolated antibody according to claim 1 and a physiologically acceptable carrier, vehicle or diluent
- 10. A pharmaceutical composition according to claim 9 wherein the microorganism is selected from the gloup consisting of Candida albicans and Saccharomyces cerevisiae.
- 11. A diagnostic kit comprising an antibody according to claim 1 and means for detecting binding by that antibody.
- 12. An isolated antibody generated against a peptide region of the Int1p protein of Candida albicans involved in the activation of the int1p propeptide.
- 13. An isolated antibody according to claim 12 wherein the peptide region is selected from the group consisting of the propeptide region at amino acids 1-263, the Catalytic domain 1 at amino acids 435-639, the Catalytic domain 2 at amino acids 738-949, and the Processing domain motif at amino acids 1022-1236 of the amino acid sequence depicted in Fig. 1.
- 14. An isolated antibody according to claim 12 wherein said antibody is capable of preventing the cleaving of the propertide.
  - 15. Isolated antisera containing an antibody according to claim 12.

18.

- 16. A method of treating or preventing an infection by a microorganism expressing the Int1p protein comprising administering an effective amount of the antibody according to claim 12 to a human or animal patient.
- 17. A diagnostic kit comprising an antibody according to claim 12 and means for detecting binding by that antibody.
- 18. An isolated peptide selected from the group consisting of the propeptide region at amino acids 1-263, the Catalytic domain 1 at amino acids 435-639, the Catalytic domain 2 at amino acids 738-949, and the Processing domain motif at amino acids 1022-1236 of the amino acid sequence depicted in Fig. 1.
- 19. A method of generating an antibody comprising introducing a peptide according to claim 18 in a host capable of generating antibodies thereto.
- 20. An isolated nucleic acid sequence coding for the peptide according to claim 18.
- 21. A method of inducing an immunological response comprising administering to a patient a peptide according to claim 18.
- 22. A vaccine comprising a peptide according to claim 18 in an amount effective to generate an immunological response.
- 23. An isolated monoclonal antibody raised against the peptide of claim
- 24. A method of diagnosing an infection by a microorganism capable of expressing an Int1p protein comprising introducing an antibody according to

claim 12 into a sample suspected of having an infection by an Int1p-producing microorganism and determining the binding of said antibody to said sample.

- 25. A method according to claim 24 wherein the microorganism is selected from the group consisting of *Candida albicans* and *Saccharomyces* cerevisiae.
- 26. A method of treating or preventing infections caused by microorganisms expressing the Int1p protein comprising administering an effective amount of an agent that inhibits Int1p activity.
- 27. A method according to dlaim 26 wherein the agent modulates a peptide region or motif from the Int1p protein which is involved in the pathway of activation for the Int1p protein.
- 28. A method according to claim 26 wherein the agent modulates a peptide selected from the group consisting of the propertide region at amino acids 1-263, the Catalytic domain 1 at amino acids 435-639, the Catalytic domain 2 at amino acids 738-949, and the Processing domain motif at amino acids 1022-1236 of the amino acid sequence depicted in Fig. 1.
- 29. A method according to claim 26 wherein the microorganism is a yeast of the Candida species.
- 30. A method according to claim 26 wherein the microorganism is selected from the group consisting of *Candida albicans* and *Saccharomyces* cerevisiae.